SELLAS Reports Strong Cash Position and Extended Runway, Confirms Arbitration Loss
SLS has more than doubled off its 52-week low of $1.39.
Summary
SELLAS Life Sciences reported a strong cash balance of $138.3 million, primarily from warrant exercises, extending its operational runway, but also confirmed an adverse arbitration ruling that dismissed claims for $191.5 million in potential milestones.
Key Events · Earnings and Guidance · SLS
-
Strong Cash Position and Runway
The company reported $138.3 million in cash and cash equivalents as of June 30, 2026, and expects this to fund operations for at least the next twelve months, with no 'going concern' doubt.
-
Significant Capital Infusion from Warrant Exercises
SELLAS received $82.9 million from the exercise of 48.8 million outstanding warrants during the six months ended June 30, 2026, at a weighted average exercise price of $1.70 per share. This follows a partial disclosure of $28.7 million on June 2, 2026.
-
Arbitration Loss Confirmed
The company confirmed an adverse arbitration ruling on July 24, 2026, dismissing its claims against 3D Medicines for $191.5 million in potential milestone payments and incurring a $1.0 million charge for legal and administrative fees. This was previously disclosed in an 8-K on July 27, 2026.
-
Increased Operating Expenses
Research and development expenses increased to $11.4 million (from $7.1 million year-over-year) and general and administrative expenses rose to $8.5 million (from $5.9 million year-over-year) for the six months ended June 30, 2026, driven by clinical trial progress and arbitration costs.
Analysis · SLS · Life Sciences
This quarterly report confirms SELLAS's robust cash position of $138.3 million, largely bolstered by $82.9 million from warrant exercises during the first half of 2026. This funding is critical for a clinical-stage biotech and extends the company's operational runway for at least the next twelve months. However, the report also details the adverse arbitration ruling against 3D Medicines, dismissing claims for $191.5 million in potential future milestones and incurring a $1.0 million charge, which is a significant loss of potential future revenue.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLS was trading at $11.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $1.39 to $15.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.